Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celularity (CELU) Cash & Equivalents (2020 - 2025)

Celularity (CELU) has disclosed Cash & Equivalents for 6 consecutive years, with $120000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents fell 9.77% to $120000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $120000.0, a 9.77% decrease, with the full-year FY2024 number at $738000.0, up 225.11% from a year prior.
  • Cash & Equivalents was $120000.0 for Q3 2025 at Celularity, down from $863000.0 in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $72.7 million in Q3 2021 to a low of $211.0 in Q2 2021.
  • A 5-year average of $13.1 million and a median of $738000.0 in 2024 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: tumbled 99.97% in 2021, then soared 167551.99% in 2022.
  • Celularity's Cash & Equivalents stood at $37.2 million in 2021, then plummeted by 62.5% to $14.0 million in 2022, then plummeted by 98.37% to $227000.0 in 2023, then skyrocketed by 225.11% to $738000.0 in 2024, then crashed by 83.74% to $120000.0 in 2025.
  • Per Business Quant, the three most recent readings for CELU's Cash & Equivalents are $120000.0 (Q3 2025), $863000.0 (Q2 2025), and $293000.0 (Q1 2025).